1. |
Wu SM, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol, 2019, 18(4): 394-405.
|
2. |
Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol, 2006, 5(7): 603-612.
|
3. |
Liu M, Counsell C, Sandercock P. Report of randomized controlled trials identifified in the Chinese literature vs. MEDLINE. JAMA, 1998, 280(15): 1308-1309.
|
4. |
He S, Wu S, Zeng Q, et al. Assessment of methodological quality and outcome measures of acute stroke randomized controlled trials in China in recent 15 years. J Evid Based Med, 2012, 5(3): 174-182.
|
5. |
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018. 中华神经科杂志, 2018, 51(9): 666-682.
|
6. |
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014. 中华神经科杂志, 2015, 48(4): 258-273.
|
7. |
Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane, 2019. [2020-02-01]. https://training.cochrane.org/handbook/current.
|
8. |
刘鸣, 吴波, 袁强. 我国急性脑卒中临床试验疗效判断方法分析. 中国循证医学杂志, 2004, 4(3): 164-166.
|
9. |
Wade DT. Measurement in neurological rehabilitation. Oxford, England: Oxford University Press, 1992: 682-686.
|
10. |
全国降纤酶临床再评价研究协作组. 降纤酶治疗急性脑梗死的临床再评价—多中心前瞻性随机双盲对照研究. 中华神经科杂志, 2000, 33(5): 263-267.
|
11. |
全国降纤酶临床再评价研究协作组. 降纤酶治疗急性脑梗死的临床再评价(II). 中华神经科杂志, 2005, 38(1): 11-16.
|
12. |
Liu X, Wang L, Wen A, et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke - a randomized, double-blind, placebo-controlled, multicenter trial. Eur J Neurol, 2012, 19(6): 855-863.
|
13. |
Zhang S, Wu B, Liu M, et al. Acupuncture efficacy on ischemic stroke recovery: multicenter randomized controlled trial in China. Stroke, 2015, 46(5): 1301-1306.
|
14. |
Zhao JW, Su YY, Zhang Y, et al. Decompressive hemicraniectomy in malignant middle cerebral artery infarct: a randomized controlled trial enrolling patients up to 80 years old. Neurocrit Care, 2012, 17(2): 161-171.
|
15. |
Peng B, Ni J, Anderson CS, et al. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China. Stroke, 2014, 45(2): 515-519.
|
16. |
Juszczak E, Altman DG, Hopewell S, et al. Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. JAMA, 2019, 321(16): 1610-1620.
|
17. |
何俐, 韩钊, 刘鸣, 等. 我国神经疾病防治性研究随机对照试验现状的初步分析. 中华神经科杂志, 1999, 32(2): 92-94.
|
18. |
Charles P, Giraudeau B, Dechartres A, et al. Reporting of sample size calculation in randomised controlled trials: review. BMJ, 2009, 338: b1732.
|
19. |
Luengo-Fernandez R, Paul NL, Gray AM, et al. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke, 2013, 44(10): 2854-2861.
|
20. |
Stinear CM, Lang CE, Zeiler S, et al. Advances and challenges in stroke rehabilitation. Lancet Neurol, 2020, 19(4): 348-360.
|